Peptide Mafia: Strategy and Roadmap

Prepared for: Stan, Alton, Jared, Nick Date: April 21, 2026 Working name: Peptide Mafia (internal only)

Executive Summary

The peptide market in April 2026 looks structurally identical to cannabis in 2015 and crypto in 2016: exploding end-consumer demand, fragmented and opaque supply, no trusted aggregator, no quality scoring layer, social-graph-dependent trust, and an imminent regulatory shift that will create permanent winners. In each of those prior waves, the companies that captured the most long-term value were not the product brands. They were the infrastructure layers: Haus in cannabis, Coinbase in crypto, Angel List in startups, G2 in software. Those companies owned the data, the trust, and the rails, and everyone else rented from them.

The four of us have a rare combination for this specific moment: agent-build velocity (Stan, Alton), marketplace operator experience (Nick), GTM validation discipline (Jared), design quality as a competitive moat (Stan), existing supply relationships (Alton), distribution chops and influencer infrastructure (Nick), and a personal understanding of the peptide user (Nick is four weeks in, Alton is running it himself). Collectively we can move faster than a funded competitor and with more rigor than a solo builder.

The business we should build is a peptide data and rails layer. B2B marketplace and operator tooling first, because ROI is fastest and the space is empty. Consumer agent layered in on the same data foundation once B2B is producing revenue. Private label at the top as a Phase 3 move. Content as the wedge throughout. AI as invisible back-end scaffolding, never the brand.

The losing path is the one we are closest to walking: building a consumer peptide agent without validating demand in a channel, shipping another product nobody buys, and burning the window RFK is about to open.

I. Asset Inventory: What Each of Us Actually Brings

This section is not flattery. It is the honest inventory of what each person contributes that the other three cannot replicate.

Stan

Design velocity and design quality as a competitive moat (TIME Best Inventions recognition, FairShake track record).
Product judgment, specifically the instinct to cut scope and ship.
The Consul infrastructure: agent architecture, deployment patterns, UX primitives.
The Cassius content agent in progress, which can be pointed at peptide content on Week 1.
Design-first brand thinking.
A 4-phase consumer agent model already drafted: Introduction, Consultation, Sourcing, Coaching.

Alton

Agent engineering depth and architectural thinking.
Supply-side relationships: Raja (compounding pharmacy owner), Isaac (China sourcing, can reach any manufacturer in one call), Liam's network.
Strategic pattern matching (Haus, Angel List, Kirkland model frames).
The Peptide Index concept as the foundational data layer.
Cloud Code cost arbitrage: agent compute costs that are 10 to 20x cheaper than anyone else's.
Personal validation as a peptide user running 40 to 50 Claude chats to manage his own protocol.

Jared

GTM rigor: the Martine framework, hypothesis-first operating philosophy.
Scar tissue from launching products nobody bought, and the discipline that came from it.
The Kalos reference point ($5M in revenue with zero software).
The SOC-2-for-peptides compliance thesis.
The agencies-become-productized-SaaS thesis (agents make agencies 10x, flipping the model).
Story and analogy as a strategic tool (which is how narrative positioning actually gets written).
A network of operators currently running GTM experiments.

Nick

A functioning marketplace (Grow World) with real operator playbooks. G2-style reviews, trial marketplace mechanics, supplier relationships, UGC affiliate systems already in prototype.
Distribution: YouTube and Instagram operating experience.
Mexico and LatAm market access with working supply chain (buddy's marketplace already lands shipments through customs).
Personal peptide user credibility.
Deep knowledge of marketplace business model mechanics (the Alibaba masterclass, Grow World margin model).
Influencer relationships and the "favorite person's stack" concept.

II. Strategic Tensions (and How We Resolve Them)

The conversation surfaced four genuine tensions. Pretending they are not there is how this falls apart three months in.

Tension 1: Validate first (Jared) vs. Build to validate (Alton)

These are not actually opposed if we separate them into different validation types.

Channel validation is Jared's specialty: does paid demand exist in a specific distribution channel before we write code? Answered with content.
Design validation is Alton's specialty: will a specific user buy when shown a mockup? Answered with Cloud Design prototypes and demos.
Resolution: Both run in parallel during the validation sprint. Content tests channel demand. Mockups test willingness to pay from specific operators. Neither gates the other. Code only ships after one of them confirms.

Tension 2: Consumer vs. B2B

Both are viable. Starting with both is how small teams die.

Resolution: B2B first. Nick's argument is structurally correct: same sales motion for 1 vial or 1,000, no competition in the B2B layer, fastest path to ROI. Consumer comes second and is powered by the same Peptide Index data layer built for B2B. This is the Angel List pattern: infrastructure first, consumer layer on top.

Tension 3: Race to the bottom concerns (Alton) vs. Own the margin (Stan)

Resolution: Never own manufacturing or compounding. Own the data, own the trust, own the rails. This is Zillow, not Coldwell Banker. If we ever sell private label, it is Phase 3 after the rails are profitable on their own.

Tension 4: Speed (Stan, Alton) vs. Rigor (Jared)

Resolution: Box validation tightly. A two-week validation sprint is short enough that Stan and Alton do not lose momentum and long enough that Jared's discipline actually gets applied. Hard stop at Day 14 with a go/no-go decision per hypothesis.

III. Core Thesis

The market moment

Peptide demand is exploding. RFK is opening the regulatory door on roughly 15 peptides. Social proof is compounding weekly.
Supply is fragmented, opaque, and low-trust. Users fall back on friend referrals because no trusted source exists.
Quality is unmeasured. Price is transparent. The gap is the entire opportunity.
Distribution is the scarce resource in 2026, not code. UGC and creator trust are the new rails.

The thesis in one sentence

Own the data, trust, and rails of the peptide market for operators and consumers before a funded competitor does, using content to validate demand and agent infrastructure to run the business at a fraction of competitor cost.

Why the window is short

RFK's regulatory shift creates a forcing function. Every funded health-and-wellness team sees the same opportunity.
Claude, OpenAI, and others currently refuse peptide sourcing queries. That gap closes the moment one of them loosens policy.
Cannabis, crypto, and startup aggregation were all winner-take-most. Peptides will be the same.
Every week we ship content without a destination is a week of leverage compounding for someone else.

IV. What the Business Actually Is

The product stack (built in this order)

Layer 1: The Peptide Index (foundation, shared across every product above it)

Comprehensive scraped database of peptide suppliers, compounding pharmacies, research sources, and reference data.
Quality scoring layer (reviews, third-party testing data, operator-reported signals).
Pricing data layer.
Regulatory status layer (pegged to the RFK-driven reclassification list).
This is the non-negotiable foundation. Every product above it is a lens on this data.

Layer 2: B2B Market Network (first revenue-generating product)

Supplier directory and data license for clinic operators, compounding pharmacies, and new entrants.
Auto-outreach and "claim your profile" Yelp model for suppliers.
Trial marketplace mechanics (Grow World playbook): operator tries before they bulk order.
Initial monetization: marketplace subscription + transaction fee (Alibaba model, not Grow World model) to avoid regulatory exposure on our side of the transaction.

Layer 3: B2B Productized Services (Jared's wedge, fast revenue)

AI ad agency for longevity clinics and peptide operators. Uses Cassius-style content automation applied to paid ad creative.
SOC-2-for-peptides compliance tooling for compounding pharmacies.
Drop-ship ancillaries: syringes, alcohol pads, bacteriostatic water.
These are productized agency plays. They generate cash, build operator relationships, and feed the Peptide Index with operator-side data.

Layer 4: Consumer Agent (built on proven foundation)

Stan's 4-phase model: Introduction, Consultation, Sourcing, Coaching.
Alton's Find-My-Peptide / Protocol agent pattern.
AI invisible in the brand. Surfaces as "your personal peptide research assistant" or similar framing.
Drives traffic to the marketplace layer. Takes affiliate or referral fees on sourcing.

Layer 5: UGC and Creator Infrastructure (Nick's wedge)

"Favorite Person's Stack" feature: type in a creator, see their published protocol.
Full commerce plumbing for influencers: profiles, attribution, order tracking, no Shopify required.
Revenue share model with creators.
This is the distribution moat. Owns the trust layer of the market.

Layer 6: Private Label (Phase 3, only after the rails are profitable)

Kirkland model on top of proven marketplace flow.
White-label from existing compounding partners.
Never touch manufacturing directly.
This is upside, not the plan.

What the business is NOT

Not a direct-to-consumer peptide brand. That is a commodity race.
Not a compounding pharmacy. That is a regulatory trap.
Not venture-funded. Revenue-first, agent-arbitrage-funded.
Not dependent on the word "peptide" in the brand. That limits us the moment the category evolves.
Not AI-forward in the marketing. AI scaffolds the back end, never the front.

V. Strategic Principles

These are the non-negotiables. If we violate them, we lose.

Own the data layer before anything else. The Peptide Index is the moat.
B2B before consumer. Revenue before brand.
Validate in channel before committing code. Two-week hard-stop sprints.
Never touch manufacturing. Own the rails, not the product.
Content is the wedge. Every content piece we ship is also a hypothesis test.
AI is back-end only. Trust is the front-end product.
Regulatory tailwind dictates content priority. SEO-dominate peptides that are about to become federally available.
Distribution is a moat, not a tactic. UGC infrastructure gets built as a product, not a marketing channel.
Agent arbitrage funds everything. Cloud Code max plans make our unit economics structurally better than any funded competitor.
Decisions get made in the group chat, not inherited from prior calls.

VI. Phased Roadmap

Phase 0: Alignment (this week)

Founder conversation: cap table structure, entity question, equity split framework.
Commit the four of us in writing (group chat first, paper later).
Agree on the validation sprint scope.
Assign role ownership (see Section VII).

Phase 1: Validation Sprint (Weeks 1 to 2)

Goal: prove demand exists in a specific channel before writing any product code.

Content tests (Nick lead): Ship 15 to 20 pieces of short-form content across Instagram, YouTube Shorts, and Twitter. Three hypotheses tested: (1) "what does this peptide do" explainer content, (2) "my stack" creator-style content, (3) "where to buy" sourcing content. Measure: engagement rate, DM inquiries, signup rate on a simple landing page.
Operator interviews (Jared lead): 20 conversations with clinic operators, compounding pharmacy owners, and longevity-clinic founders. Questions pre-written. Goal: validate the B2B supplier-database thesis and the SOC-2-for-peptides thesis. Kalos-style: no software shown, just the problem conversation.
Mockup validation (Stan lead): Cloud Design prototypes of the supplier directory and the consumer agent. Shown to 10 operators and 10 consumers. Measure: "would you pay X for this today" commitment.
Technical groundwork (Alton lead): Peptide Index schema, scraping infrastructure, data model, integration plan with Consul parent infrastructure.
Hard go/no-go gate at Day 14. Hypotheses that pass get built. Hypotheses that fail get killed.

Phase 2: Peptide Index + B2B MVP (Weeks 3 to 8)

Goal: ship revenue-generating B2B product.

Build and populate the Peptide Index (Alton).
Launch supplier directory with Yelp model auto-outreach (Stan design, Alton build).
Launch first productized service that passed validation (likely AI ad agency for clinics, Jared operates).
Continue content production via Cassius (Stan and Nick feed content calendar).
Begin UGC creator outreach (Nick).
First revenue target: $10K MRR by Week 8.

Phase 3: Consumer Agent + Creator Infrastructure (Months 3 to 6)

Goal: launch the consumer layer on proven B2B foundation.

Ship consumer agent using Stan's 4-phase model.
Launch "Favorite Person's Stack" creator infrastructure (Nick).
Layer SOC-2-for-peptides compliance product if operator interviews validated it (Jared).
Aggressive SEO and GEO targeting the RFK-legalization list.
First consumer revenue target: $25K MRR by Month 6 across all products.

Phase 4: Market Depth + Mexico/LatAm (Months 6 to 12)

Goal: become the default infrastructure.

Expand Peptide Index internationally. Nick leads Mexico entry.
Deepen UGC creator network (50-plus creators with published stacks).
Begin private-label conversations with compounding partners (Alton's Raja, Isaac networks).
Target: $100K MRR by Month 12.

Phase 5: Kirkland Layer and Moat Compounding (Month 12+)

Goal: own the category the way Haus owns cannabis equipment.

Launch private label on proven flow.
Acquire adjacent content properties and creator channels.
Regulatory maturity: be the compliance and trust layer when federal rules settle.

VII. Role Allocation

Titles for internal clarity. Negotiate formal titles later.

Stan: Product and Design

Owns: consumer-facing design, agent UX, brand system, Cassius content production, creative direction.
Primary deliverables Phase 1: validation mockups, brand identity work (no "peptide" in name, no AI in surface).
Primary deliverables Phase 2: Peptide Index UX, supplier directory UX, B2B product design.
Primary deliverables Phase 3: consumer agent shipping.

Alton: Technology and Supply

Owns: agent infrastructure, Peptide Index data architecture, Cloud Code arbitrage, supply-side relationships, technical strategy.
Primary deliverables Phase 1: scraping pipeline, schema, supply relationship mapping via Raja and Isaac.
Primary deliverables Phase 2: Peptide Index live, B2B product backend, Cassius integration.
Primary deliverables Phase 3: consumer agent backbone, protocol tracking engine.

Jared: Growth and GTM

Owns: validation rigor, operator sales motion, productized agency wedges, hypothesis tests, B2B revenue.
Primary deliverables Phase 1: operator interviews, validation framework execution, go/no-go decisions.
Primary deliverables Phase 2: AI ad agency for clinics as first productized service, first B2B customers.
Primary deliverables Phase 3: SOC-2-for-peptides compliance product if validated.

Nick: Marketplace, Distribution, and International

Owns: marketplace mechanics, UGC and creator infrastructure, content distribution, Mexico/LatAm market.
Primary deliverables Phase 1: content hypothesis tests across IG/YT/Twitter, creator outreach list, Grow World playbook adaptation.
Primary deliverables Phase 2: creator infrastructure prototype, supplier onboarding playbook.
Primary deliverables Phase 3: "Favorite Person's Stack" launch, Mexico beachhead.

Shared

Strategy, positioning, and pricing decisions are group decisions.
Hiring and partnerships are group decisions.
Capital allocation is a group decision.

VIII. Capital Strategy

No VC. Jared and Alton are both explicitly against. Stan is mid-raise on Consul, and conflating the two is bad for Consul's pitch.
Bootstrap from productized service revenue (Jared's wedge) in Phase 2.
Reinvest into Peptide Index completeness and consumer agent build.
Consider a small friends-and-family round only if a specific regulatory moment creates a time-sensitive expansion opportunity we cannot fund from operations.
Agent arbitrage via Cloud Code max plans means our burn for compute is effectively 10 to 20x lower than a funded competitor running on raw API costs. This is a structural advantage worth protecting.

IX. The First 30 Days (Concrete)

This week

Group chat live. Name: Peptide Mafia.
Founder conversation on cap table and entity structure.
Sprint scope agreed by Friday.

Week 1

Nick ships first 5 content pieces.
Jared books 10 operator interviews.
Stan designs 2 Cloud Design mockups (supplier directory, consumer agent).
Alton ships scraping infrastructure v1 and schema.

Week 2

Nick ships remaining content and tracks metrics.
Jared completes 20 operator interviews and synthesizes findings.
Stan runs mockup validation with 20 target users.
Alton has Peptide Index v0 populated with 100+ suppliers.
Day 14: go/no-go meeting. Hypotheses sorted into ship, kill, or further-test buckets.

Weeks 3 and 4

Build sprint on validated hypotheses.
First productized service listed and sold.
First B2B customer onboarded.

X. Key Risks

Market risks

A funded competitor (Hims-backed, Ro-backed, Function-Health-backed) launches first with deeper pockets. Mitigation: our data layer becomes the moat, and we can be acquired or partnered with rather than displaced.
Regulatory reversal: RFK's policies get rolled back. Mitigation: we are platform-agnostic, and the underlying demand is not regulation-dependent.
AI model providers open up peptide sourcing queries. Mitigation: trust and curation matter more than raw model access. We are not competing on model capability.

Team risks

Four-way alignment drift. Mitigation: weekly group syncs with written decisions logged. Group chat for async. No inherited decisions from private calls.
Time conflict with our other commitments (Consul fundraise, Grow World, Jared's pivot). Mitigation: role boundaries are clear. Peptide Mafia is a second priority for everyone but cannot become a zero priority for anyone.

Execution risks

Shipping before validating. Mitigation: hard go/no-go gate at Day 14.
Over-scoping Phase 1. Mitigation: sprint scope is locked before sprint starts.
Brand confusion between Peptide Mafia and Consul / Generative / Grow World. Mitigation: standalone brand, standalone entity (to be decided in founder conversation).

XI. Success Metrics

Phase 1 (Day 14)

3+ validated hypotheses with demonstrated demand.
100+ suppliers in Peptide Index.
20 operator conversations logged with synthesis.
1+ Letter of Intent or paid pilot from a B2B operator.

Phase 2 (Week 8)

$10K MRR.
500+ suppliers in Peptide Index.
5+ B2B customers.
50+ pieces of content shipped with measured performance.

Phase 3 (Month 6)

$25K MRR across products.
Consumer agent live with first 1,000 users.
20+ creators onboarded to UGC infrastructure.
10K email subscribers on the peptide newsletter.

Phase 4 (Month 12)

$100K MRR.
Mexico beachhead established.
50+ creators on Favorite Person's Stack.
Default infrastructure positioning in the category.

XII. Open Questions for the Group

Entity: standalone Peptide Mafia LLC, or a product line under Generative Inc., or a Grow World subsidiary?
Equity split across the four of us.
Time commitment expectation per person per week in Phase 1.
Brand name. "Peptide Mafia" is internal only. Alton's rule is no "peptide" in the public brand and no AI in the public brand. What does that leave us with?
First productized service to ship: AI ad agency for clinics, supplier data license, or SOC-2-for-peptides tool? All three passed the conversation. Only one should ship first.
How do we handle conflicts with Consul fundraising optics?
Mexico first or US first for international expansion?

Closing Frame

We are not building a peptide brand. We are building the infrastructure layer that every peptide brand, clinic, and creator will depend on in 24 months. We do it without VC. We do it on agent arbitrage economics that a funded competitor cannot match. We do it with rigor Jared will enforce and velocity Stan and Alton will supply and distribution Nick already has running. The window is open right now. It will not be open in a year.